Page 22 - Read Online

Page 16 of 20 Manrique et al. Microbiome Res Rep 2024;3:23 https://dx.doi.org/10.20517/mrr.2023.80

34. Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut 2020;69:1510-9. DOI PubMed PMC
35. Doestzada M, Vila AV, Zhernakova A, et al. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell
2018;9:432-45. DOI PubMed PMC
36. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut
bacteria and their genes. Nature 2019;570:462-7. DOI PubMed PMC
37. Lima S, Rupert A, Jin W, et al. The gut microbiome regulates efficacy of sulfasalazine therapy for spondyloarthritis in inflammatory
bowel disease. Inflamm Bowel Dis 2023;29:S72-3. DOI
38. Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes,
contributing to the therapeutic effects of the drug. Nat Med 2017;23:850-8. DOI
39. Ahmadi S, Razazan A, Nagpal R, et al. Metformin reduces aging-related leaky gut and improves cognitive function by beneficially
modulating gut microbiome/goblet cell/mucin axis. J Gerontol A Biol Sci Med Sci 2020;75:e9-21. DOI PubMed PMC
40. Zhu X, Shen J, Feng S, et al. Akkermansia muciniphila, which is enriched in the gut microbiota by metformin, improves cognitive
function in aged mice by reducing the proinflammatory cytokine interleukin-6. Microbiome 2023;11:120. DOI PubMed PMC
41. Ting NLN, Lau HCH, Yu J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut
2022;71:1412-25. DOI PubMed PMC
42. Haiser HJ, Seim KL, Balskus EP, Turnbaugh PJ. Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our
understanding of its pharmacokinetics. Gut Microbes 2014;5:233-8. DOI PubMed PMC
43. Dobkin JF, Saha JR, Butler VPB Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science
1983;220:325-7. DOI PubMed
44. Rekdal VM, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for
Levodopa metabolism. Science 2019;364:eaau6323. DOI PubMed PMC
45. Zhang Y, He X, Mo C, et al. Association between microbial tyrosine decarboxylase gene and levodopa responsiveness in patients
with Parkinson disease. Neurology 2022;99:e2443-53. DOI
46. Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the
chemotherapeutic drug gemcitabine. Science 2017;357:1156-60. DOI
47. Luo Y, Zhou T. Connecting the dots: targeting the microbiome in drug toxicity. Med Res Rev 2022;42:83-111. DOI PubMed
48. Mahdy MS, Azmy AF, Dishisha T, et al. Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-
associated toxicity. BMC Microbiol 2023;23:53. DOI PubMed PMC
49. Chamseddine AN, Ducreux M, Armand JP, et al. Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-
induced diarrhea severity. Pharmacol Ther 2019;199:1-15. DOI
50. Parvez MM, Basit A, Jariwala PB, et al. Quantitative investigation of Irinotecan metabolism, transport, and gut microbiome
activation. Drug Metab Dispos 2021;49:683-93. DOI PubMed PMC
51. Takeno S, Sakai T. Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to
nitroreduction. Teratology 1991;44:209-14. DOI PubMed
52. Konishi K, Fukami T, Gotoh S, Nakajima M. Identification of enzymes responsible for nitrazepam metabolism and toxicity in human.
Biochem Pharmacol 2017;140:150-60. DOI PubMed
53. Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and
toxicity. Nat Rev Gastroenterol Hepatol 2017;14:356-65. DOI PubMed
54. Pinto-Cardoso S, Klatt NR, Reyes-Terán G. Impact of antiretroviral drugs on the microbiome: unknown answers to important
questions. Curr Opin HIV AIDS 2018;13:53-60. DOI PubMed PMC
55. Rueda-Ruzafa L, Cruz F, Cardona D, et al. Opioid system influences gut-brain axis: dysbiosis and related alterations. Pharmacol Res
2020;159:104928. DOI
56. Meng J, Yu H, Ma J, et al. Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-
dependent manner. PLoS One 2013;8:e54040. DOI PubMed PMC
57. Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor
microenvironment. Science 2013;342:967-70. DOI PubMed PMC
58. Derosa L, Routy B, Fidelle M, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell
carcinoma patients. Eur Urol 2020;78:195-206. DOI
59. Kennedy K, Khaddour K, Ramnath N, Weinberg F. The lung microbiome in carcinogenesis and immunotherapy treatment. Cancer J
2023;29:61-9. DOI PubMed
60. Wei L, Wen XS, Xian CJ. Chemotherapy-induced intestinal microbiota dysbiosis impairs mucosal homeostasis by modulating toll-
like receptor signaling pathways. Int J Mol Sci 2021;22:9474. DOI PubMed PMC
61. Le Bastard Q, Ward T, Sidiropoulos D, et al. Fecal microbiota transplantation reverses antibiotic and chemotherapy-induced gut
dysbiosis in mice. Sci Rep 2018;8:6219. DOI PubMed PMC
62. Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-
induced colitis. Nat Commun 2016;7:10391. DOI PubMed PMC
63. van der Hee B, Wells JM. Microbial regulation of host physiology by short-chain fatty acids. Trends Microbiol 2021;29:700-12. DOI
PubMed
64. Rios-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, de los Reyes-Gavilán CG, Salazar N. Intestinal short chain fatty acids